Introduction
The glucoincretin hormone glucagon-like peptide-1 (GLP-1) is derived from a proglucagon precursor and secreted by intestinal entero-endocrine L-cells in response to oral nutrient ingestion (Kieffer and Habener, 1999; Holst, 2007; Lovshin and Drucker, 2009; Mundil et al., 2012) . The majority of circulating GLP-1 levels comprise the 30-amino acid peptide GLP-1(7-36)amide, which acts through a seven transmembrane-spanning, heterotrimeric class B G-protein coupled receptor on pancreatic β cells to exert glucoregulatory and insulinotropic actions (Thorens, 1992) . However, after its secretion from the intestine, native GLP-1(7-36)amide is rapidly degraded (half-life (t 1/2 ) = 1-2 min) on its N-and C-terminus by the ubiquitously expressed enzymes dipeptidyl peptidase-IV (DPP-IV) and neutral endopeptidase 24.11 (NEP) (Hansen et al., 1999; Holst, 2007) , respectively, to yield GLP-1(9-36)amide and nonapeptide GLP-1(28-36)amide as metabolites (Mentlein et al., 1999; Deacon et al., 1995a,b; Hupe-Sodman et al., 1995) . In patients with type 2 diabetes mellitus, secretion of GLP-1 is diminished, and administration of either DPP-IV inhibitors (e.g., sitagliptin) or exogenous GLP-1 analogs (e.g., exenatide and liraglutide) represent potential therapeutic options in the treatment of type 2 diabetes mellitus (Moore and Saudek, 2008; Edwards, 2013) .
Until recently, GLP-1(9-36)amide, the major circulating human metabolite of GLP-1(7-36)amide (Deacon et al., 1995a,b) , was thought to be an inactive metabolite of GLP-1 due to its weak, if any, insulinotropic activity. However, growing evidence has suggested that GLP-1(9-36)amide possesses unique extrapancreatic insulin-like actions in the heart, vasculature, and liver, which appear to be mediated independently of the GLP-1 receptor (Abu-Hamdah et al., 2009; Tomas and Habener, 2010) . For instance, in vivo administration of GLP-1(9-36)amide has demonstrated cardioprotective effects in dogs, rat, and mice, which arises from elevation in DMD #54254 6 myocardial glucose uptake, and from protection against ischemia-reperfusion injury (Nikolaidis et al., 2005; Sonne et al., 2008; Ban et al., 2008) . Likewise, infusions of GLP-1(9-36)amide into obese, insulin-resistant human subjects significantly lowered hepatic glucose production in a insulin-independent fashion, suggesting that GLP-1(9-36)amide lowers plasma glucose in the insulin resistant subjects via direct inhibition of hepatic glucose production (Elahi et al., 2008) .
The NEP cleavage product GLP-1(28-36)amide also has been shown to inhibit weight gain, accumulation of liver triglycerides, and improve insulin sensitivity in diet-induced obese mice (Tomas et al., 2011a) . Consistent with the in vivo observations, Tomas et al. (2010) recently demonstrated that GLP-1(9-36)amide suppressed glucose production in isolate mouse hepatocytes by 30% over a dose range of 0.1 to 100 μM independently of the GLP-1 receptor.
Furthermore, in a follow-on study by the same authors (Tomas et al., 2011b) , dose-dependent (0.01-10 μM) suppression of mitochondrial glucose production and oxidative stress by ~ 50% was also demonstrated in mouse hepatocytes with amide. In the case of GLP-1(28-36)amide, cytoprotective action was enhanced (0.1-100 nM) when a "solubilizing" formulation was used (Liu et al., 2012) .
Towards this end, we became interested in examining the in vitro hepatocyte stability of GLP-1(9-36)amide and GLP-1(28-36)amide especially since hepatic endopeptidases including DPP-IV and/or NEP (Elovson, 1980; Roques et al., 1993; Yasojima et al., 2001; Itou et al., 2013) , bear the potential to cleave the two GLP-1(7-36)amide metabolites into additional N-and C-truncated products with unique pharmacologic activity. In the present work, we have examined the metabolic stability of GLP-1(9-36)amide and GLP-1(28-36)amide in cryopreserved mouse as well as human hepatocytes using a novel liquid chromatography tandem mass spectrometry (LC-MS/MS) assay for the quantitation of intact GLP-1(9-36)amide and This article has not been copyedited and formatted. The final version may differ from this version. GLP-1(28-36)amide, respectively, in the incubations. A facile decline of the GLP-1(7-36)amide metabolites in the hepatocyte incubations (e.g., t 1/2 < 1 hour in mouse hepatocytes) led to a detailed characterization of their metabolic fate. Our in vitro findings raise the intriguing possibility that the inhibitory effects of GLP-1(9-36)amide and GLP-1(28-36)amide on gluconeogenesis and oxidative stress might be due, at least in part, to the actions of additional downstream metabolites, which are obtained from the enzymatic cleavage of the peptide backbone in the parent compounds.
Materials and Methods
Materials. GLP-1(9-36)amide (EGTFTSDVSSYLEGQAAKEFIAWLVKGRamide) and GLP-1(28-36)amide (FIAWLVKGRamide) were synthesized by solid phase synthesis and purified by sequential HPLC to >95% single component homogeneity. Description of the synthetic methodology is provided in the Supplemental Method section. Gibco William's E Medium (WEM) supplemented with L-glutamine and without phenol red or sodium bicarbonate, pooled hepatocytes from human (pool of 10 livers from male/female), and pooled hepatocytes from male CD-1 mice were purchased from Celsis In Vitro Technologies (Baltimore, MD).
Bovine serum albumin (BSA), sodium bicarbonate, diprotin A and HEPES were purchased from Sigma-Aldrich (St. Louis, MO). Phosphoramidon was purchased from R & D Systems (Minneapolis, MN). Solvents used for analysis were of analytical or HPLC grade (Fisher Scientific, Pittsburgh, PA).
Incubations in Hepatocytes.
WEM was prepared by adding 26 mM sodium carbonate and 50 mM HEPES, followed by 0.2 µm filtration then 30 minutes of CO 2 bubbling at 37 °C. This media was used for thawing and suspension of hepatocytes. Stock solutions of GLP-1(9-36)amide and GLP-1(28-36)amide were prepared in water at 1 mM and diluted to 5 µM in DMD #54254 8 WEM. Incubations were conducted in 96-well flat-bottom polystyrene plate. Stability assessments were done in duplicate. Mouse and human hepatocytes were suspended at 0.5 million viable cells per ml WEM and prewarmed at 37 °C for 30 min. Incubations were initiated with the addition of peptide stocks (final concentration in incubation = 1 μM) and were conducted at 37 °C,75% relative humidity, and 5% CO 2 . The total incubation volume was 0.1 ml per well. To assess the role of NEP and DPP-IV in GLP-1(9-36) and GLP-1(28-36) cleavage, human hepatocyte stability of the two peptides was also examined in the presence of the NEP inhibitor phosphoramidon (1000 μM) and the DPP-IV inhibitor diprotin A (500 μM) (Gandhi et al., 1993; Roden et al., 1994; Ura et al., 1987; Turner et al., 2001; Malm-Erjefält et al., 2010) , respectively, in triplicate. Inhibitor concentrations were based on experiments described in aforementioned references, and were not optimized in the present work. Phosphoramidon was purchased as a solution in methanol, which was dried down then reconstituted in WEM prior to use. Aliquots (50 μl) of the reaction mixture at zero, 5, 10, 15, 30, 60, 90, and 120 metabolite identification studies, protein precipitation and LC-MS/MS sample wells that contained GLP-1(9-36)amide were pre-treated with an acetonitrile/BSA slurry to combat compound loss due to non-specific binding. Thus, 100 µl of a mixture containing 1 part 40 mg/ml BSA in water and 3 parts acetonitrile was added to wells of Eppendorf Protein LoBind deepwell 96 polypropylene plates. The plates were left uncapped overnight at room temperature to allow the mixture to evaporate. Similarly, GLP-1(9-36)amide hepatocyte incubation plates were soaked with an aqueous solution of BSA. A solution of 100 mg/ml BSA in water was added to 24-well (600 µl) and 96-well (100 µl) plates and allowed to sit overnight at room temperature. This solution was thoroughly aspirated from the wells and discarded prior to incubating. Low retention pipette tips (Thermo Fisher Scientific-Molecular BioProducts, Hopkinton, MA) were used throughout the operation. Acetonitrile was used for protein precipitation of GLP-1(28-36)amide and ethanol for GLP-1(9-36)amide. Briefly, samples were injected as is by partial loop injection and were separated from interferences on an Acquity BEH300 C18 column (50 x 2.1 mm, 1.7 µm) (Waters, Milford, MA) by gradient elution. The mobile phase consisted of 0.1% aqueous formic acid (solvent A) and 0.1% formic acid in acetonitrile (solvent B) flowing at 0.4 ml/min. The linear gradient program used was as follows: 10% B 0-0.5 min; 10-90% B 0.5-3.0 min, held at 90% B from 3.0-3.5 minutes, step back to initial conditions and hold for 1.0 minute. The most abundant precursor DMD #54254 optimization on each platform is highly recommended for the purposes of quantitation.
LC-MS/MS
Calibration standards were prepared separately for each matrix type using the same matrix pool as was used in the incubation samples to normalize for matrix effects. All standards were fit by least-squares regression of their areas to a weighted equation (linear for GLP-1(28-36)amide; quadratic for GLP-1(9-36)amide), from which the unknown concentrations were calculated.
Dynamic range was 5.0-2000 nM for both analyses. Accuracy and precision were not qualified in these studies.
LC-MS/MS Methodology for Metabolite Identification Studies.
Analysis of GLP-1(9-36)amide and its metabolites was performed using an Acella auto-sampler, degasser/pump assembly, photodiode array detector and an Orbitrap Elite mass spectrometer (Thermoscientific, West Palm Beach, FL). An Acquity UPLC BEH C18, 130Å, 1.7 µm, 2.1 X 150 mm column (Milford, MA) was used to achieve chromatographic separation. The mobile phase consisted of 0.1% aqueous formic acid (solvent A) and acetonitrile (solvent B) flowing at 0.3 ml/min. The linear gradient program used was as follows: 5% B 0-2 min; 50% B 25 min; 95% B 26.5-28.5
min; 5% B 29-34 min. The spray potential was 3.5 V and heated capillary was at 265 °C.
Samples were analyzed in the positive ion mode by full scan mass measurements from 50-1000 DMD #54254
1 1 amu at a resolution of 15,000, with one data-dependent acquisition scan of the most intense ion in scan event 1. Product-ion spectra were acquired at a normalized collision energy of 65eV
with an isolation width of 2 amu.
Analysis of GLP-1(28-36)amide its metabolites was performed using a Surveyor auto-sampler, degasser/pump assembly, photodiode array detector, and an Orbitrap XL mass spectrometer (Thermoscientific, West Palm Beach, FL) operating in positive electrospray mode. A Phenomenex Hydro RP-C18, 3.5 μm, 150 x 4.6 mm column (Phenomenex, Torrance, CA) was used to achieve chromatographic separation. The mobile phase consisted of 0.1% aqueous formic acid (solvent A) and acetonitrile (solvent B) flowing at 1.0 ml/min. The linear gradient program used was as follows: 5% B 0-3 min; 10% B 3 min; 95% B 33-36 min; 5% B 38-45 min.
The spray potential was 4 V and heated capillary was at 275 °C. Samples were analyzed by full scan mass measurements from 50-1000 amu at a resolution of 15,000, with two data-dependent acquisition scans of the most intense ion in scan event 1 and 2, respectively. Product-ion spectra were acquired at a normalized collision energy of 65eV with an isolation width of 2 amu.
The ProteinProspector tool v 5.10.11 (http://prospector.ucsf.edu/prospector/mshome.htm) (University of California, San Francisco, CA) was used for deconvolution of parent and metabolite full scan and daughter spectra. Standard methodology for elucidating fragment ions of peptides was applied. For example, fragments derived from the carboxy terminus were designated as "y" ions, whereas fragment ions derived from the amino terminal were designated as "b" ions (Wysocki et al., 2005) . Likewise, "a" fragment ions corresponded to loss of CO from "b" fragment ions (Wysocki et al., 2005; Medzihradszky, 2005) .
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Incubation volume was 0.1 ml and cell density in the incubations was 0.5 x 10 6 /ml.
Results
Hepatocyte Stability of GLP-1(9-36) and GLP-1(28-36)amides. To assess hepatocyte stability, GLP-1(9-36)amide and GLP-1(28-36)amide at a concentration of approximately 1 μ M were incubated discretely in mouse and human hepatocytes at 37 °C for 2 hr. Periodically, aliquots of the incubation mixture were examined for depletion of the two peptides ( Figure 1 ). Table 1 summarizes the t 1/2 and CL int,app for depletion of GLP-1(9-36)amide and GLP-1(28-36)amide in mouse and human hepatocytes. Co-treatment of human hepatocytes with the NEP inhibitor phosphoramidon (1000 μM) or the DPP-IV inhibitor diprotin A (500 μM) had virtually no effect on the stability of the GLP-1(9-36)amide and GLP-1(28-36)amide (data not shown).
Metabolic Profile of GLP-1(9-36)amide and GLP-1(28-36)amide in Mouse and Human
Hepatocytes. Figure 2 depicts the extracted ion chromatograms of mouse (panel A) and human (panel B) hepatocyte incubations with GLP-1(9-36)amide (20 μM) conducted at 37 °C for 2 and 4 hours, respectively. A total of 13 and 10 metabolites were formed upon incubating GLP-1(9-36)amide in mouse and human hepatocytes, respectively. Figure 3 ). This is because, for larger peptides, the 12 C isotope does not have the highest isotopic distribution.
As seen in Table 2 , all of the metabolites of GLP-1(9-36)amide were derived from cleavage across the peptide backbone. Metabolites M9 and M11-M13 were only observed in mouse hepatocyte incubations, whereas metabolites M1-M8 and M10 were observed in hepatocyte incubations from both species. The CID spectra of metabolites M1-M13 with structural assignments of observed fragment ions are depicted in Supplementary Figures 1-13 Table 3 This article has not been copyedited and formatted. The final version may differ from this version. Figure 5 and 
Discussion
Previous studies (Deacon et al., 1995a (Deacon et al., ,b, 1996 Mentlein et al., 1993; Mentlein, 1999) Metabolism at the C-terminus was not observed for both peptides. For GLP-1(9-36)amide, a total of 13 N-terminus cleavage products were observed in hepatocytes incubations. Some species differences were noted with respect to metabolites formed. significantly impact the susceptibility of the two peptides towards proteolysis implying that hepatic NEP does not play a role in the metabolism of the two peptides. Overall, the finding (particularly in human hepatocytes) is consistent with the fact that no GLP-1(7-36)amide metabolites (including GLP-1(28-36)amide) formed by recombinant human NEP were detected in our human hepatocytes incubations with GLP-1(9-36)amide. Likewise, the DPP-IV inhibitor diprotin A failed to induce resistance towards proteolytic cleavage of GLP-1(9-36)amide and GLP-1(28-36)amide in mouse and human hepatocytes. This observation is consistent with our preliminary findings that demonstrate the rat, dog and human plasma stability of GLP-1(9-36)amide and GLP-1(28-36)amide (t 1/2 > 240 min in all species). Under identical experimental conditions, the t 1/2 of GLP-1(7-36)amide in rat, dog and human was estimated to be 44, 150 and 100 minutes, respectively. Overall, these studies imply that plasma/hepatic DPP-IV activity does not appear to play a role in the metabolism of the two GLP-1(7-36)amide peptide metabolites.
As such, additional mechanistic studies will be required to identify the endopeptidase ( In vitro stability of at ASPET Journals on April 8, 2017
